{"id":"https://openalex.org/W2467444511","doi":"https://doi.org/10.1200/jco.2013.31.6_suppl.20","title":"Long-term responders to enzalutamide (ENZA) during the phase III AFFIRM trial: Baseline characteristics and efficacy outcomes.","display_name":"Long-term responders to enzalutamide (ENZA) during the phase III AFFIRM trial: Baseline characteristics and efficacy outcomes.","publication_year":2013,"publication_date":"2013-02-20","ids":{"openalex":"https://openalex.org/W2467444511","doi":"https://doi.org/10.1200/jco.2013.31.6_suppl.20","mag":"2467444511"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2013.31.6_suppl.20","doi":"https://doi.org/10.1200/jco.2013.31.6_suppl.20","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2013.31.6_suppl.20","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5081246052","display_name":"Mark T. Fleming","orcid":"https://orcid.org/0000-0001-9120-9587","observed_orcids":["https://orcid.org/0000-0001-9120-9587"]},"institutions":[{"id":"https://openalex.org/I4210088931","display_name":"Virginia Oncology Associates","ror":"https://ror.org/009yyqs39","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210088931"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark T. Fleming","raw_affiliation_strings":["Virginia Oncology Associates, Norfolk, VA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Virginia Oncology Associates, Norfolk, VA","institution_ids":["https://openalex.org/I4210088931"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072850546","display_name":"Howard I. Scher","orcid":"https://orcid.org/0000-0002-6791-9324","observed_orcids":["https://orcid.org/0000-0002-6791-9324"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]},{"id":"https://openalex.org/I4405269141","display_name":"Sidney Kimmel Center for Prostate and Urologic Cancers","ror":"https://ror.org/037e5pc19","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4405269141"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Howard I. Scher","raw_affiliation_strings":["Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555","https://openalex.org/I4405269141"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007779528","display_name":"Karim S. Fizazi","orcid":"https://orcid.org/0000-0002-6068-9474","observed_orcids":["https://orcid.org/0000-0002-6068-9474"]},"institutions":[{"id":"https://openalex.org/I102197404","display_name":"Universit\u00e9 Paris-Sud","ror":"https://ror.org/028rypz17","country_code":"FR","type":"education","lineage":["https://openalex.org/I102197404","https://openalex.org/I277688954"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Karim Fizazi","raw_affiliation_strings":["University of Paris Sud, Orsay, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Paris Sud, Orsay, France","institution_ids":["https://openalex.org/I102197404"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023517416","display_name":"Mary\u2010Ellen Taplin","orcid":"https://orcid.org/0000-0002-3384-0300","observed_orcids":["https://orcid.org/0000-0002-3384-0300"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mary-Ellen Taplin","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016173669","display_name":"David Forer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267655","display_name":"Medivation, Inc. (United States)","ror":"https://ror.org/03rkn0606","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267655"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Forer","raw_affiliation_strings":["Medivation, Inc., San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medivation, Inc., San Francisco, CA","institution_ids":["https://openalex.org/I4405267655"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078059658","display_name":"Mohammad Hirmand","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267655","display_name":"Medivation, Inc. (United States)","ror":"https://ror.org/03rkn0606","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267655"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mohammad Hirmand","raw_affiliation_strings":["Medivation, Inc., San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medivation, Inc., San Francisco, CA","institution_ids":["https://openalex.org/I4405267655"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5072378199","display_name":"Johann Sebastian De Bono","orcid":"https://orcid.org/0000-0002-2034-595X","observed_orcids":["https://orcid.org/0000-0002-2034-595X"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Johann Sebastian De Bono","raw_affiliation_strings":["The Institute of Cancer Research, Sutton, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Institute of Cancer Research, Sutton, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"31","issue":"6_suppl","first_page":"20","last_page":"20"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10124","display_name":"Prostate Cancer Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/enzalutamide","display_name":"enzalutamide","score":1.0},{"id":"https://openalex.org/keywords/castration-resistant-prostate-cancer","display_name":"castration-resistant prostate cancer","score":0.9110000133514404},{"id":"https://openalex.org/keywords/long-term-responders","display_name":"long-term responders","score":0.8569999933242798},{"id":"https://openalex.org/keywords/androgen-receptor-antagonists","display_name":"androgen receptor antagonists","score":0.8809999823570251},{"id":"https://openalex.org/keywords/affirm-trial","display_name":"AFFIRM trial","score":0.8569999933242798},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8960000276565552},{"id":"https://openalex.org/keywords/psa-response","display_name":"PSA response","score":0.8479999899864197},{"id":"https://openalex.org/keywords/treatment-duration","display_name":"treatment duration","score":0.621999979019165}],"concepts":[{"id":"https://openalex.org/C2776551883","wikidata":"https://www.wikidata.org/wiki/Q1996756","display_name":"Enzalutamide","level":5,"score":0.8921493887901306},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7718988656997681},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5545027256011963},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.5116141438484192},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4906972646713257},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.45637333393096924},{"id":"https://openalex.org/C187960798","wikidata":"https://www.wikidata.org/wiki/Q7631152","display_name":"Subgroup analysis","level":3,"score":0.45474880933761597},{"id":"https://openalex.org/C61943457","wikidata":"https://www.wikidata.org/wiki/Q6046661","display_name":"Interim analysis","level":3,"score":0.43930521607398987},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.43492719531059265},{"id":"https://openalex.org/C29456083","wikidata":"https://www.wikidata.org/wiki/Q1221899","display_name":"Gynecology","level":1,"score":0.395449697971344},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.31807941198349},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3090789020061493},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.187587171792984},{"id":"https://openalex.org/C61367390","wikidata":"https://www.wikidata.org/wiki/Q416601","display_name":"Androgen receptor","level":4,"score":0.18515697121620178},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.15727394819259644},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2013.31.6_suppl.20","doi":"https://doi.org/10.1200/jco.2013.31.6_suppl.20","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2013.31.6_suppl.20","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.7699999809265137}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4254085726","https://openalex.org/W4206539093","https://openalex.org/W2605272107","https://openalex.org/W2590629494","https://openalex.org/W2168063883","https://openalex.org/W7098857331","https://openalex.org/W2601659212","https://openalex.org/W2590244275","https://openalex.org/W2116708359","https://openalex.org/W2109783350"],"abstract_inverted_index":{"20":[0],"Background:":[1],"ENZA,":[2],"an":[3],"oral":[4],"androgen":[5],"receptor":[6],"inhibitor,":[7],"was":[8,77,83,108,196],"shown":[9],"to":[10,68,99,150,187,228],"significantly":[11],"increase":[12],"overall":[13,78],"survival":[14,79],"by":[15,110],"4.8":[16],"mo":[17],"(P":[18],"<0.001,":[19],"HR":[20],"0.63)":[21],"vs":[22,166,201],"placebo":[23],"(PBO)":[24],"in":[25,31,59,93,178,198,203,220],"AFFIRM,":[26],"a":[27],"phase":[28],"III":[29],"trial":[30,247],"patients":[32],"(pts)":[33],"with":[34,161],"castration":[35],"resistant":[36],"prostate":[37,162],"cancer":[38,163],"(CRPC)":[39],"post-":[40],"docetaxel.":[41],"Here":[42],"we":[43],"report":[44],"the":[45,60,86,94,130,147,151,155,179,204,229],"baseline":[46,175,240],"characteristics":[47],"and":[48,169,241],"efficacy":[49,184,244],"outcomes":[50,185],"of":[51,129,218],"long-term":[52],"responders":[53],"(LTR,":[54],"\u226512":[55,225],"months":[56],"on":[57,101,134],"ENZA)":[58],"AFFIRM":[61,221],"trial.":[62],"Methods:":[63],"Pts":[64,92,177],"were":[65,97,133],"randomized":[66],"2:1":[67],"ENZA":[69,95,102,131,153,189,206,223,231],"160":[70],"mg/day":[71],"or":[72],"PBO.":[73],"The":[74,81,105],"primary":[75],"endpoint":[76],"(OS).":[80],"study":[82],"stopped":[84],"at":[85,174,239],"pre-specified":[87],"interim":[88,119],"analysis":[89,120],"(520":[90],"events).":[91],"group":[96,107,132],"allowed":[98],"continue":[100],"post":[103],"unblinding.":[104],"LTR":[106,148,156,180,199,233],"defined":[109],"Aug":[111],"2012":[112],"data":[113,116,121],"cut-off.":[114],"Efficacy":[115],"are":[117,209],"from":[118,123],"cut-off":[122],"Sep":[124],"2011.":[125],"Results:":[126],"35%":[127,217],"(276/800)":[128],"therapy":[135],"for":[136,142,224],"\u2265":[137],"12":[138],"months;":[139],"22%":[140],"(174/800)":[141],">":[143],"18":[144],"months.":[145,226],"Comparing":[146],"subgroup":[149,157,181,200],"all":[152,188,205,230],"group,":[154,232],"had":[158,170,182,235,242],"been":[159],"living":[160],"longer":[164],"(7.9":[165],"5.9":[167],"yrs)":[168],"lower":[171],"disease":[172,237],"burden":[173,238],"(Table).":[176],"improved":[183,243],"compared":[186],"group.":[190,207],"Of":[191],"note,":[192],"50%":[193],"PSA":[194],"response":[195],"87%":[197],"54%":[202],"Results":[208],"preliminary,":[210],"updated":[211],"results":[212],"will":[213],"be":[214],"presented.":[215],"Conclusions:":[216],"pts":[219,234],"received":[222],"Compared":[227],"less":[236],"outcomes.":[245],"Clinical":[246],"information:":[248],"NCT00974311.":[249],"[Table:":[250],"see":[251],"text]":[252]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":2}],"updated_date":"2026-09-25T08:18:29.962427","created_date":"2016-07-22T00:00:00"}